Key Takeaways
- • Astorg has agreed to acquire Thermo Fisher Scientific's microbiology business for approximately $1 billion, with deal closure expected in the second half of 2026.
- • The microbiology unit generated $645 million in revenue in the prior year, providing antimicrobial susceptibility testing and culture media solutions across clinical, pharmaceutical, and food safety testing applications.
- • The divestiture represents Thermo Fisher's continued portfolio optimization, while Astorg expands its exposure to specialized life sciences and diagnostic testing markets.
Summary
Astorg, the European mid-market private equity firm, has agreed to acquire Thermo Fisher Scientific's microbiology business for approximately $1 billion. The transaction represents a significant entry for Astorg into the specialized microbiology and diagnostics segment, an area serving clinical, pharmaceutical, and food safety testing markets globally.
The microbiology unit being divested generated $645 million in revenue during the most recent fiscal year, demonstrating a material revenue base and established market position. The business provides antimicrobial susceptibility testing solutions and culture media products, which serve as essential components in clinical diagnostics, pharmaceutical development, and food safety compliance workflows. These markets have shown sustained demand driven by regulatory requirements, infection control protocols, and pharmaceutical quality assurance needs.
Thermo Fisher Scientific expects the transaction to close in the second half of 2026, providing a defined timeline for completion. The sale aligns with Thermo Fisher's ongoing strategy of optimizing its portfolio to focus on core growth areas and higher-margin businesses. For Astorg, the acquisition represents an opportunity to acquire a stable, cash-generating business with diversified end-market exposure across healthcare, pharmaceutical manufacturing, and food safety sectors.
The transaction underscores continued activity in the life sciences and diagnostics sector among mid-market private equity buyers, particularly for established businesses with recurring revenue streams and defensible market positions.
The microbiology unit being divested generated $645 million in revenue during the most recent fiscal year, demonstrating a material revenue base and established market position. The business provides antimicrobial susceptibility testing solutions and culture media products, which serve as essential components in clinical diagnostics, pharmaceutical development, and food safety compliance workflows. These markets have shown sustained demand driven by regulatory requirements, infection control protocols, and pharmaceutical quality assurance needs.
Thermo Fisher Scientific expects the transaction to close in the second half of 2026, providing a defined timeline for completion. The sale aligns with Thermo Fisher's ongoing strategy of optimizing its portfolio to focus on core growth areas and higher-margin businesses. For Astorg, the acquisition represents an opportunity to acquire a stable, cash-generating business with diversified end-market exposure across healthcare, pharmaceutical manufacturing, and food safety sectors.
The transaction underscores continued activity in the life sciences and diagnostics sector among mid-market private equity buyers, particularly for established businesses with recurring revenue streams and defensible market positions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.